After Eisai and Biogen’s Alzheimer’s disease medicine Leqembi debuted to a somewhat tepid market reaction, the companies have pointed to more convenient diagnosis and administration as two factors | With the FDA approval of the first blood-based test to help diagnose Alzheimer’s disease, Eisai and Biogen’s acceleration plan for Leqembi has been set in motion. But bending the Leqembi sales curve may still take time, a Mizuho analyst argued.
